ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition

Data to be presented at ASCO in June suggests Pfizer’s Ibrance has a good shot at maintaining a leadership position in the category as competitors Lilly and Novartis step closer to the market.